Skip to content

Does lycopene bioavailability improve in tomatoes with novel lycopene compounds?

Bioavailability of novel lycopene compounds found in a variety of tomato - Analysing the uptake of lycopene in human blood of healthy adult volunteers- a randomised cross over group study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000965707
Enrollment
12
Registered
2013-08-30
Start date
2014-01-13
Completion date
2014-02-28
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Lycopene is a carotenoid, present in tomatoes, which has linked to beneficial effects on human health, such as prevention of prostate cancer. Lycopene found in human blood, plasma and tissues contain high levels of cis isomers of lycopene, whereas the trans isomer is the main dietary source of lycopene. Interestingly, processing of tomatoes converts trans isomers to cis isomers and the latter being regarded as more bioavailable, since they are more soluble and better absorbed in the gut. Although it should be noted that isomerisation may also take place in vivo. Processing of food can lead to loss of beneficial nutrients and therefore being able to consume fresh unprocessed tomatoes rich in cis isomer lycopene rather than a processed tomato product may provide additional nutritional benefits.

Interventions

Intervention is, consumption of one dose of tomato, containing 5-20 mg of novel tetra-cis lycopene or containing 5-20 mg standard trans-lycopene. A blood sample will be obtained at 0, 4, 5 and 6 hours and a urine sample will be obtained at 0 and 24 h. There will be a 2 week wash out peroid before consumption of one dose of the altenative variety of tomato. Samples are collected as with the first dose.

Sponsors

The New Zealand Institute of Plant and Food Research
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Healthy adults Pre-screened for normal blood lipid profiles (fasting cholesterol less than 5.2 nmol/L and fasting Plasma-triacylglycerol (TAG) rich lipoprotein Less than 2.3 nmol/L)

Exclusion criteria

Smokers, Frequent alcohol consumption Pregnant women, Regular prescribed medication affecting lipid metabolism, Regular use of carotenoid containing supplements, BMI under18.5 or over 35, Long term illness requiring active treatment (cancer, gastrointestinal disease, cardiovascular disease, diabetes) Regular use of antacids and laxatives (more than once a week), Not willing to discontinue foods containing tomato, guava, watermelon, grapefruit, dried parsley or basil, persimmons, liver pate, asparagus, red cabbage, chillies, papaya or carotenoid containing supplements, laxatives and antacids 1 week prior to and during the trial period. Have donated blood within 16 wk of first sample, Has taken antibiotics within 4 weeks before study start date. Fasting cholesterol greater than 5.2 mmol/L and fasting Plasma-triacylglycerol (TAG) rich lipoprotein greater than 2.3 mmol/L.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026